AU2001255596A1 - Compounds and methods for treatment and diagnosis of chlamydial infection - Google Patents
Compounds and methods for treatment and diagnosis of chlamydial infectionInfo
- Publication number
- AU2001255596A1 AU2001255596A1 AU2001255596A AU5559601A AU2001255596A1 AU 2001255596 A1 AU2001255596 A1 AU 2001255596A1 AU 2001255596 A AU2001255596 A AU 2001255596A AU 5559601 A AU5559601 A AU 5559601A AU 2001255596 A1 AU2001255596 A1 AU 2001255596A1
- Authority
- AU
- Australia
- Prior art keywords
- polypeptides
- compounds
- chlamydial infection
- diagnosis
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 206010061041 Chlamydial infection Diseases 0.000 title abstract 3
- 201000000902 chlamydia Diseases 0.000 title abstract 3
- 208000012538 chlamydia trachomatis infectious disease Diseases 0.000 title abstract 3
- 150000001875 compounds Chemical class 0.000 title abstract 3
- 238000003745 diagnosis Methods 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- 229920001184 polypeptide Polymers 0.000 abstract 5
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 5
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 5
- 108091028043 Nucleic acid sequence Proteins 0.000 abstract 3
- 238000001514 detection method Methods 0.000 abstract 2
- 241000606161 Chlamydia Species 0.000 abstract 1
- 238000009007 Diagnostic Kit Methods 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 230000000890 antigenic effect Effects 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 239000012472 biological sample Substances 0.000 abstract 1
- 239000003153 chemical reaction reagent Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 229960005486 vaccine Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/295—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Chlamydiales (O)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
- A61K39/4622—Antigen presenting cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4648—Bacterial antigens
- A61K39/464835—Chlamydiaceae, e.g. Chlamydia trachomatis or Chlamydia psittaci
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Cell Biology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Mycology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Compounds and methods for the diagnosis and treatment of Chlamydial infection are disclosed. The compounds provided include polypeptides that contain at least one antigenic portion of a Chlamydia antigen and DNA sequences encoding such polypeptides. Pharmaceutical compositions and vaccines comprising such polypeptides or DNA sequences are also provided, together with antibodies directed against such polypeptides. Diagnostic kits containing such polypeptides or DNA sequences and a suitable detection reagent may be used for the detection of Chlamydial infection in patients and in biological samples.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US19885300P | 2000-04-21 | 2000-04-21 | |
US60/198,853 | 2000-04-21 | ||
US21975200P | 2000-07-20 | 2000-07-20 | |
US60/219,752 | 2000-07-20 | ||
PCT/US2001/013081 WO2001081379A2 (en) | 2000-04-21 | 2001-04-23 | Compounds and methods for treatment and diagnosis of chlamydial infection |
Publications (1)
Publication Number | Publication Date |
---|---|
AU2001255596A1 true AU2001255596A1 (en) | 2001-11-07 |
Family
ID=26894210
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2001255596A Abandoned AU2001255596A1 (en) | 2000-04-21 | 2001-04-23 | Compounds and methods for treatment and diagnosis of chlamydial infection |
Country Status (8)
Country | Link |
---|---|
US (2) | US20030175700A1 (en) |
EP (2) | EP1278855B1 (en) |
AT (1) | ATE389020T1 (en) |
AU (1) | AU2001255596A1 (en) |
CA (1) | CA2407114A1 (en) |
DE (1) | DE60133190T2 (en) |
ES (1) | ES2303525T3 (en) |
WO (1) | WO2001081379A2 (en) |
Families Citing this family (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5629167A (en) * | 1994-04-19 | 1997-05-13 | Biocine S.P.A. | Detection of antibodies against Chlamydia trachomatis pgp3 antigen in patient sera by enzyme-linked immunosorbent assay |
EP1105490A1 (en) | 1998-08-20 | 2001-06-13 | Aventis Pasteur Limited | Nucleic acid molecules encoding inclusion membrane protein c of chlamydia |
CA2340283A1 (en) | 1998-08-20 | 2000-03-02 | Aventis Pasteur Limited | Nucleic acid molecules encoding pomp91a protein of chlamydia |
US6686339B1 (en) | 1998-08-20 | 2004-02-03 | Aventis Pasteur Limited | Nucleic acid molecules encoding inclusion membrane protein C of Chlamydia |
US6649370B1 (en) | 1998-10-28 | 2003-11-18 | Aventis Pasteur Limited | Chlamydia antigens and corresponding DNA fragments and uses thereof |
US6607730B1 (en) | 1998-11-02 | 2003-08-19 | Aventis Pasteur Limited/Aventis Pasteur Limitee | Chlamydia antigens and corresponding DNA fragments and uses thereof |
US20020094340A1 (en) | 1998-12-01 | 2002-07-18 | Andrew D. Murdin | Chlamydia antigens and corresponding dna thereof |
JP2002531129A (en) | 1998-12-08 | 2002-09-24 | コリクサ コーポレイション | Compounds and methods for treatment and diagnosis of chlamydia infection |
US20020061848A1 (en) * | 2000-07-20 | 2002-05-23 | Ajay Bhatia | Compounds and methods for treatment and diagnosis of chlamydial infection |
US20080213264A1 (en) * | 1998-12-08 | 2008-09-04 | Corixa Corporation | Compounds and methods for treatment and diagnosis of chlamydial infection |
GB9828000D0 (en) | 1998-12-18 | 1999-02-10 | Chiron Spa | Antigens |
US7297341B1 (en) | 1998-12-23 | 2007-11-20 | Sanofi Pasteur Limited | Chlamydia antigens and corresponding DNA fragments and uses thereof |
US6808713B1 (en) | 1998-12-28 | 2004-10-26 | Aventis Pasteur Limited | Chlamydia antigens and corresponding DNA fragments and uses thereof |
DE69938059T2 (en) | 1998-12-28 | 2009-01-08 | Sanofi Pasteur Ltd., Toronto | CHLAMYDIA ANTIGENE, CORRESPONDING DNA FRAGMENTS AND ITS USES |
GB9902555D0 (en) | 1999-02-05 | 1999-03-24 | Neutec Pharma Plc | Medicament |
EP2172214A3 (en) | 1999-03-12 | 2011-03-16 | Aventis Pasteur Limited | Chlamydia antigens and corresponding DNA fragments and uses thereof |
WO2000066739A2 (en) | 1999-05-03 | 2000-11-09 | Aventis Pasteur Limited | Chlamydia antigens and corresponding dna fragments and uses thereof |
JP4667694B2 (en) | 1999-09-20 | 2011-04-13 | サノフィ、パストゥール、リミテッド | Chlamydia antigen and corresponding DNA fragments and uses thereof |
US6632663B1 (en) | 1999-09-22 | 2003-10-14 | Aventis Pasteur Limited | DNA immunization against chlamydia infection |
NZ520200A (en) | 1999-12-22 | 2004-04-30 | Aventis Pasteur | Polynucleotides encoding the Clamydia pneumoniae polypeptides omp P6 precursor gene product |
US6919187B2 (en) * | 2000-04-21 | 2005-07-19 | Corixa Corporation | Compounds and methods for treatment and diagnosis of chlamydial infection |
WO2001081379A2 (en) | 2000-04-21 | 2001-11-01 | Corixa Corporation | Compounds and methods for treatment and diagnosis of chlamydial infection |
EP1282718B1 (en) | 2000-05-08 | 2006-12-20 | Sanofi Pasteur Limited | Chlamydia antigens and corresponding dna fragments and uses thereof |
AU2001276619A1 (en) | 2000-07-03 | 2002-01-14 | Chiron S.P.A. | Immunisation against chlamydia pneumoniae |
JP4413617B2 (en) | 2001-12-12 | 2010-02-10 | カイロン ソチエタ ア レスポンサビリタ リミタータ | Immunization against CHLAMYDIATRACHOMATIS |
GB0203403D0 (en) | 2002-02-13 | 2002-04-03 | Chiron Spa | Chlamydia cytotoxic-T cell epitopes |
WO2004073492A2 (en) * | 2003-02-14 | 2004-09-02 | Massachusetts Eye And Ear Infirmary | Chlamydia pneumoniae associated chronic intraocular disorders and treatment thereof |
JP2008534594A (en) | 2005-03-31 | 2008-08-28 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | Vaccines against Chlamydia infection |
US8541007B2 (en) | 2005-03-31 | 2013-09-24 | Glaxosmithkline Biologicals S.A. | Vaccines against chlamydial infection |
EP1981905B1 (en) * | 2006-01-16 | 2016-08-31 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES | Chlamydia vaccine |
CA2744739A1 (en) * | 2007-12-03 | 2009-06-11 | President And Fellows Of Harvard College | Chlamydia antigens |
WO2010047515A2 (en) | 2008-10-20 | 2010-04-29 | 광주과학기술원 | Bipodal peptide binder |
EP2403526B1 (en) | 2009-03-06 | 2019-05-15 | GlaxoSmithKline Biologicals SA | Chlamydia antigens |
JP5811086B2 (en) * | 2010-03-23 | 2015-11-11 | 和光純薬工業株式会社 | Primer and probe for detecting Chlamydia trachomatis, and method for detecting chlamydia trachomatis using the same |
US8892184B2 (en) | 2010-10-18 | 2014-11-18 | Siemens Medical Solutions Usa, Inc. | Systems and methods for reducing interference in a dual modality imaging system |
WO2013044398A1 (en) * | 2011-09-30 | 2013-04-04 | The University Of British Columbia | Chlamydia antigen compositions and uses thereof |
Family Cites Families (77)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4237224A (en) | 1974-11-04 | 1980-12-02 | Board Of Trustees Of The Leland Stanford Jr. University | Process for producing biologically functional molecular chimeras |
US4118469A (en) * | 1976-04-27 | 1978-10-03 | Research Corporation | Antigen for trachoma lymphogranuloma venereum (LGV) and non-gonococcal urethritis (NGU) |
US4235877A (en) | 1979-06-27 | 1980-11-25 | Merck & Co., Inc. | Liposome particle containing viral or bacterial antigenic subunit |
US4554101A (en) | 1981-01-09 | 1985-11-19 | New York Blood Center, Inc. | Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity |
US4603112A (en) | 1981-12-24 | 1986-07-29 | Health Research, Incorporated | Modified vaccinia virus |
US4769330A (en) | 1981-12-24 | 1988-09-06 | Health Research, Incorporated | Modified vaccinia virus and methods for making and using the same |
US4497899A (en) * | 1982-04-12 | 1985-02-05 | Abbott Laboratories | Immunoassay for Chlamydia trachomatis antigens |
US4436727A (en) | 1982-05-26 | 1984-03-13 | Ribi Immunochem Research, Inc. | Refined detoxified endotoxin product |
US4866034A (en) | 1982-05-26 | 1989-09-12 | Ribi Immunochem Research Inc. | Refined detoxified endotoxin |
US4883750A (en) | 1984-12-13 | 1989-11-28 | Applied Biosystems, Inc. | Detection of specific sequences in nucleic acids |
US4751180A (en) | 1985-03-28 | 1988-06-14 | Chiron Corporation | Expression using fused genes providing for protein product |
US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
GB8508845D0 (en) | 1985-04-04 | 1985-05-09 | Hoffmann La Roche | Vaccinia dna |
US4777127A (en) | 1985-09-30 | 1988-10-11 | Labsystems Oy | Human retrovirus-related products and methods of diagnosing and treating conditions associated with said retrovirus |
US4935233A (en) | 1985-12-02 | 1990-06-19 | G. D. Searle And Company | Covalently linked polypeptide cell modulators |
US4800159A (en) | 1986-02-07 | 1989-01-24 | Cetus Corporation | Process for amplifying, detecting, and/or cloning nucleic acid sequences |
US4877611A (en) | 1986-04-15 | 1989-10-31 | Ribi Immunochem Research Inc. | Vaccine containing tumor antigens and adjuvants |
US5075109A (en) | 1986-10-24 | 1991-12-24 | Southern Research Institute | Method of potentiating an immune response |
GB8702816D0 (en) | 1987-02-07 | 1987-03-11 | Al Sumidaie A M K | Obtaining retrovirus-containing fraction |
AU622104B2 (en) | 1987-03-11 | 1992-04-02 | Sangtec Molecular Diagnostics Ab | Method of assaying of nucleic acids, a reagent combination and kit therefore |
IL86724A (en) | 1987-06-19 | 1995-01-24 | Siska Diagnostics Inc | Method and kits for the amplification and detection of nucleic acid sequences |
US4897268A (en) | 1987-08-03 | 1990-01-30 | Southern Research Institute | Drug delivery system and method of making the same |
WO1989001973A2 (en) | 1987-09-02 | 1989-03-09 | Applied Biotechnology, Inc. | Recombinant pox virus for immunization against tumor-associated antigens |
EP0359789B1 (en) | 1988-01-21 | 1993-08-04 | Genentech, Inc. | Amplification and detection of nucleic acid sequences |
CA1340807C (en) | 1988-02-24 | 1999-11-02 | Lawrence T. Malek | Nucleic acid amplification process |
AP129A (en) | 1988-06-03 | 1991-04-17 | Smithkline Biologicals S A | Expression of retrovirus gag protein eukaryotic cells |
EP0348725A3 (en) | 1988-06-29 | 1990-10-24 | Miles Inc. | Species-specific epitode of chlamydia trachomatis and antibodies that recognize the same |
US4912094B1 (en) | 1988-06-29 | 1994-02-15 | Ribi Immunochem Research Inc. | Modified lipopolysaccharides and process of preparation |
US5869608A (en) * | 1989-03-17 | 1999-02-09 | The United States Of America As Represented By The Department Of Health And Human Services | Nucleotide and amino acid sequences of the four variable domains of the major outer membrane proteins of Chlamydia trachomatis |
WO1991002805A2 (en) | 1989-08-18 | 1991-03-07 | Viagene, Inc. | Recombinant retroviruses delivering vector constructs to target cells |
US5585362A (en) | 1989-08-22 | 1996-12-17 | The Regents Of The University Of Michigan | Adenovirus vectors for gene therapy |
KR920007887B1 (en) | 1989-08-29 | 1992-09-18 | 스즈키 지도오샤 고오교오 가부시키가이샤 | Exhaust gas cleaning device for internal combustion engine |
US5616326A (en) | 1990-01-25 | 1997-04-01 | The University Court Of The University Of Glasgow | Recombinant canine adenovirus 2 (CAV-2) |
US5166053A (en) * | 1990-02-23 | 1992-11-24 | Miles Inc. | Specimen adequacy control for chlamydia assays |
JP3018553B2 (en) * | 1990-05-08 | 2000-03-13 | 日立化成工業株式会社 | Chlamydia trachomatis antibody measurement method and preparation for diagnosing chlamydia trachomatis infection |
SE466259B (en) | 1990-05-31 | 1992-01-20 | Arne Forsgren | PROTEIN D - AN IGD BINDING PROTEIN FROM HAEMOPHILUS INFLUENZAE, AND THE USE OF THIS FOR ANALYSIS, VACCINES AND PURPOSE |
US5725863A (en) * | 1991-09-06 | 1998-03-10 | The United States Of America As Represented By The Secretary Of Agriculture | Polypeptides useful in prevention of chlamydia infection |
US5518913A (en) | 1991-10-10 | 1996-05-21 | National Research Council Of Canada | High level recombinant protein production using conditional helper-free adenovirus vector |
DK0671948T3 (en) | 1992-06-25 | 1997-09-01 | Smithkline Beecham Biolog | Vaccine containing adjuvants |
EP0662083A1 (en) | 1992-09-18 | 1995-07-12 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | Synthetic peptide vaccine for chlamydia trachomatis |
FR2702160B1 (en) | 1993-03-02 | 1995-06-02 | Biovecteurs As | Synthetic particulate vectors and method of preparation. |
FR2704145B1 (en) | 1993-04-21 | 1995-07-21 | Pasteur Institut | Particulate vector and pharmaceutical composition containing it. |
GB9326253D0 (en) | 1993-12-23 | 1994-02-23 | Smithkline Beecham Biolog | Vaccines |
WO1996002555A1 (en) | 1994-07-15 | 1996-02-01 | The University Of Iowa Research Foundation | Immunomodulatory oligonucleotides |
FR2723849B1 (en) | 1994-08-31 | 1997-04-11 | Biovector Therapeutics Sa | PROCESS FOR INCREASING IMMUNOGENICITY, PRODUCT OBTAINED AND PHARMACEUTICAL COMPOSITION |
EP0784059B1 (en) | 1994-09-20 | 2009-02-11 | Hitachi Chemical Co., Ltd. | Polynucleotides encoding an antigenic polypeptide of chlamydia pneumoniae |
UA56132C2 (en) | 1995-04-25 | 2003-05-15 | Смітклайн Бічем Байолоджікалс С.А. | Vaccine composition (variants), method for stabilizing qs21 providing resistance against hydrolysis (variants), method for manufacturing vaccine |
JPH11506332A (en) | 1995-06-02 | 1999-06-08 | インサイト・ファーマスーティカルズ・インコーポレイテッド | Improved method for obtaining full-length cDNA sequences |
US5698202A (en) | 1995-06-05 | 1997-12-16 | The Wistar Institute Of Anatomy & Biology | Replication-defective adenovirus human type 5 recombinant as a rabies vaccine carrier |
GB9516293D0 (en) | 1995-08-09 | 1995-10-11 | Immunova Ltee | Novel peptides and their use as vaccines |
WO1998002546A2 (en) | 1996-07-12 | 1998-01-22 | University Of Manitoba | Dna immunization against chlamydia infection |
US6464979B1 (en) | 1996-09-12 | 2002-10-15 | Aventis Pasteur Limited | Chlamydial vaccines and methods of preparation thereof |
US7459524B1 (en) | 1997-10-02 | 2008-12-02 | Emergent Product Development Gaithersburg Inc. | Chlamydia protein, sequence and uses thereof |
KR20010032336A (en) | 1997-11-21 | 2001-04-16 | 브랑디 빠스깔 | Chlamydia pneumoniae genomic sequence and polypeptides, fragments thereof and uses thereof, in particular for the diagnosis, prevention and treatment of infection |
KR100735651B1 (en) | 1997-11-28 | 2007-07-06 | 세로노 제네틱스 인스티튜트 에스.에이. | Chlamydia trachomatis genomic sequence and polypeptides, fragments thereof and uses thereof, in particular for the diagnosis, prevention and treatment of infection |
GB9727262D0 (en) | 1997-12-24 | 1998-02-25 | Smithkline Beecham Biolog | Vaccine |
CN1629185B (en) | 1998-04-07 | 2011-11-02 | 科里克萨公司 | Fusion proteins of mycobacterium tuberculosis antigens and their uses |
EP1133572A4 (en) | 1998-11-12 | 2005-06-15 | Univ California | Chlamydia pneumoniae genome sequence |
US20020061848A1 (en) | 2000-07-20 | 2002-05-23 | Ajay Bhatia | Compounds and methods for treatment and diagnosis of chlamydial infection |
US6166177A (en) * | 1998-12-08 | 2000-12-26 | Corixa Corporation | Compounds and methods for the treatment and diagnosis of chlamydial infection |
US6565856B1 (en) * | 1998-12-08 | 2003-05-20 | Corixa Corporation | Compounds and methods for treatment and diagnosis of chlamydial infection |
US6432916B1 (en) * | 1998-12-08 | 2002-08-13 | Corixa Corporation | Compounds and methods for treatment and diagnosis of chlamydial infection |
US6448234B1 (en) * | 1998-12-08 | 2002-09-10 | Corixa Corporation | Compounds and methods for treatment and diagnosis of chlamydial infection |
JP2002531129A (en) * | 1998-12-08 | 2002-09-24 | コリクサ コーポレイション | Compounds and methods for treatment and diagnosis of chlamydia infection |
GB9828000D0 (en) | 1998-12-18 | 1999-02-10 | Chiron Spa | Antigens |
GB9902555D0 (en) | 1999-02-05 | 1999-03-24 | Neutec Pharma Plc | Medicament |
WO2000066739A2 (en) | 1999-05-03 | 2000-11-09 | Aventis Pasteur Limited | Chlamydia antigens and corresponding dna fragments and uses thereof |
JP4667694B2 (en) | 1999-09-20 | 2011-04-13 | サノフィ、パストゥール、リミテッド | Chlamydia antigen and corresponding DNA fragments and uses thereof |
US6632663B1 (en) | 1999-09-22 | 2003-10-14 | Aventis Pasteur Limited | DNA immunization against chlamydia infection |
NZ520200A (en) | 1999-12-22 | 2004-04-30 | Aventis Pasteur | Polynucleotides encoding the Clamydia pneumoniae polypeptides omp P6 precursor gene product |
US7472098B2 (en) | 2000-02-14 | 2008-12-30 | Ubs Financial Services, Inc. | System and method for execution of trades made pursuant to stock option and purchase plans |
WO2001081379A2 (en) | 2000-04-21 | 2001-11-01 | Corixa Corporation | Compounds and methods for treatment and diagnosis of chlamydial infection |
EP1282718B1 (en) | 2000-05-08 | 2006-12-20 | Sanofi Pasteur Limited | Chlamydia antigens and corresponding dna fragments and uses thereof |
AU2001276619A1 (en) | 2000-07-03 | 2002-01-14 | Chiron S.P.A. | Immunisation against chlamydia pneumoniae |
US8312249B1 (en) | 2008-10-10 | 2012-11-13 | Apple Inc. | Dynamic trampoline and structured code generation in a signed code environment |
FR2957821B1 (en) | 2010-03-24 | 2014-08-29 | Inst Francais Du Petrole | NEW AREA OF CATALYST REGENERATION DIVIDED IN SECTORS FOR REGENERATIVE CATALYTIC UNITS |
-
2001
- 2001-04-23 WO PCT/US2001/013081 patent/WO2001081379A2/en active Application Filing
- 2001-04-23 EP EP01928775A patent/EP1278855B1/en not_active Expired - Lifetime
- 2001-04-23 CA CA002407114A patent/CA2407114A1/en not_active Abandoned
- 2001-04-23 EP EP08152495A patent/EP2192128A3/en not_active Withdrawn
- 2001-04-23 AU AU2001255596A patent/AU2001255596A1/en not_active Abandoned
- 2001-04-23 DE DE60133190T patent/DE60133190T2/en not_active Expired - Fee Related
- 2001-04-23 ES ES01928775T patent/ES2303525T3/en not_active Expired - Lifetime
- 2001-04-23 US US09/841,260 patent/US20030175700A1/en not_active Abandoned
- 2001-04-23 AT AT01928775T patent/ATE389020T1/en not_active IP Right Cessation
-
2004
- 2004-01-15 US US10/762,058 patent/US7384638B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
ATE389020T1 (en) | 2008-03-15 |
EP1278855A2 (en) | 2003-01-29 |
EP2192128A2 (en) | 2010-06-02 |
CA2407114A1 (en) | 2001-11-01 |
US7384638B2 (en) | 2008-06-10 |
DE60133190D1 (en) | 2008-04-24 |
US20040137007A1 (en) | 2004-07-15 |
DE60133190T2 (en) | 2009-04-02 |
US20030175700A1 (en) | 2003-09-18 |
EP1278855B1 (en) | 2008-03-12 |
WO2001081379A2 (en) | 2001-11-01 |
WO2001081379A3 (en) | 2002-09-19 |
EP2192128A3 (en) | 2010-09-22 |
ES2303525T3 (en) | 2008-08-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2001255596A1 (en) | Compounds and methods for treatment and diagnosis of chlamydial infection | |
WO2002008267A3 (en) | Compounds and methods for treatment and diagnosis of chlamydial infection | |
WO2001040474A3 (en) | Compounds and methods for treatment and diagnosis of chlamydial infection | |
HK1044020A1 (en) | Compounds and methods for treatment and diagnosis of chlamydialinfection | |
WO2003041560A3 (en) | Compounds and methods for treatment and diagnosis of chlamydial infection | |
WO1998042740A3 (en) | Compounds and methods for the diagnosis and treatment of ehrlichia infection | |
WO2003086308A3 (en) | Compositions and methods for the diagnosis and treatment of herpes simplex virus infection | |
WO2001062893A3 (en) | Compounds and methods for diagnosis and immunotherapy of tuberculosis | |
WO2000000615A3 (en) | Compounds and methods for the diagnosis and treatment of ehrlichia infection | |
WO2002002131A3 (en) | Compositions and methods for the diagnosis and treatment of herpes simplex virus infection | |
WO2001085949A3 (en) | Compounds and methods for the diagnosis and treatment of ehrlichia infection | |
EP0834567A3 (en) | Compounds and methods for the diagnosis and treatment of Babesia microti infection | |
WO2003020108A3 (en) | Compositions and methods for the diagnosis and treatment of herpes simplex virus infection | |
WO2002053016A3 (en) | Compounds and methods for the diagnosis and treatment of babesia infection | |
WO2001085947A3 (en) | Compounds and methods for the diagnosis and treatment of babesia microti infection |